The development of the PROTAC-based drug PpD, which specifically targets PAK4, has effectively inhibited tumor cell proliferation and demonstrated strong synergistic effects when combined with PD-1 blockade immunotherapy, enhancing the immune response against RCC [128]. This evidence concerns the gene PAK4 and renal cell carcinoma.